Related Experiment Videos
[The antihypertensive and antianginal activity of Dilren--a prolonged-action calcium antagonist]
Insights
Dilren effectively treated essential hypertension and angina pectoris in patients with ischemic heart disease. This medication reduced blood pressure and improved symptoms with minimal side effects.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Essential hypertension and ischemic heart disease are significant cardiovascular conditions.
- Effective pharmacotherapy is crucial for managing these co-existing diseases.
Purpose of the Study:
- To evaluate the efficacy and safety of dilren in patients with essential hypertension and ischemic heart disease.
Main Methods:
- A 4-week treatment course of dilren (300 mg/day) was administered to 19 patients.
- Clinical assessments included bicycle exercise tests, ECG, echocardiography, and 24-hour ambulatory blood pressure monitoring.
Main Results:
- Dilren reduced hypertension in 79% and angina pectoris in 63% of patients.
- A 10-11% decrease in total peripheral vascular resistance and a 14.2/10.5 mm Hg reduction in blood pressure were observed.
- Prolonged P-Q interval occurred in 26% without atrioventricular block; side effects were mild and transient in 5.3%.
Conclusions:
- Dilren demonstrates significant efficacy in managing essential hypertension and angina pectoris in patients with ischemic heart disease.
- The drug is well-tolerated, with manageable side effects, supporting its use in this patient population.
Abstract:
A 4-week course of dilren under clinical, bicycle exercise, ECG, echo-CG control and 24-hour monitoring of AP was given to 19 subjects with essential hypertension stage I-II and ischemic heart disease. A single dose of the drug (300 mg/day) diminished hypertension and angina pectoris in 79 and 63% of the patients, respectively. A 4-week dilren produced a 10-11% decrease in the total peripheral vascular resistance, prolonged P-Q interval by 0.01-0.02 sec without atrioventricular block in 26% of the patients, reduced AP measured according to Korotkov by 14.2/10.5 mm Hg (in awake patients by 12.8/8.4 mm Hg, in sleeping ones by 8.6/4.5 mm Hg without changes in 24-h AP curve). Side effects occurred in 5.3% of the cases and were overcome without discontinuation of the treatment.